Subcutaneously administered methotrexate for rheumatoid arthritis, by prefilled syringes versus prefilled pens: patient preference and comparison of the self-injection experience
Authors Demary W, Schwenke H, Rockwitz K, Kästner P, Liebhaber A, Schoo U, Hübner G, Pichlmeier U, Guimbal-Schmolck C, Müller-Ladner U
Received 14 March 2014
Accepted for publication 2 May 2014
Published 6 August 2014 Volume 2014:8 Pages 1061—1071
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Winfried Demary,1 Holger Schwenke,2 Karin Rockwitz,3 Peter Kästner,4 Anke Liebhaber,5 Ulrich Schoo,6 Georg Hübner,7 Uwe Pichlmeier,8 Cécile Guimbal-Schmolck,8 Ulf Müller-Ladner9
1Private practice, Hildesheim, Germany; 2Private practice, Dresden, Germany; 3Private practice, Goslar, Germany; 4Outpatient Rheumatism Center, Erfurt, Germany; 5Private practice, Halle, Germany; 6Private practice, Rheine, Germany; 7Private practice, Lingen, Germany; 8medac GmbH, Hamburg, Germany; 9Department of Rheumatology and Clinical Immunology, Kerckhoff-Klinik GmbH, Bad Nauheim, Germany
Purpose: This multicenter, randomized, crossover study compared preference, ease of use, acceptability, satisfaction, and safety of repeated subcutaneous (SC) self-administrations with prefilled pens and prefilled syringes delivering methotrexate (MTX), in patients with rheumatoid arthritis (RA).
Patients and methods: The study (ClinicalTrials.gov number NCT01793259) enrolled 120 patients requiring initiation or intensification of MTX therapy for RA. Patients were randomized to receive the test drug, a prefilled pen (Metex® PEN/Metoject® PEN), or the reference drug, a prefilled syringe (Metex®/Metoject®), at doses of 15, 17.5, or 20 mg MTX SC once a week for 3 weeks. This was followed by receipt of the reference drug (prefilled syringe) or the test drug (prefilled pen) in a crossover design, with each patient serving as his/her own control. Questionnaires regarding patient preference, the Self-Injection Assessment Questionnaire (SIAQ), and diaries regarding local tolerability were used to document outcomes.
Results: Overall patient preference for the MTX prefilled pen was 75% (P<0.0001). In a six-item questionnaire, 73% to 76% of the patients preferred the prefilled pen in relation to use, acceptability, and satisfaction, and 67% of the patients confirmed that it did not take much effort to overcome SC self-injection with the pen. The SIAQ showed no clinical differences, in any domain scores, between both devices. Overall patient attitude towards self-injection at baseline was positive, as was patient experience with both devices during the study. As well, 92% of physicians and study nurses indicated that they would recommend the MTX prefilled pen to patients for future MTX treatment. The formulations were generally well tolerated.
Conclusion: SC self-injection of MTX with a prefilled pen was generally preferred, by patients with RA, over a prefilled syringe with regard to use, acceptability, and satisfaction. This is supported by the strong appreciation of their attending study nurses and physicians, for its convenience.
Keywords: methotrexate, injection device
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]